Bellevue Life Sciences Unit 1 Com & Wt Exp
| 10.66 | +0.0800 | +0.76% | Vol 8.40K | 1Y Perf - |
| Sep 20th, 2023 15:59 DELAYED |
| BID | 10.63 | ASK | 10.92 | ||
| Open | 10.60 | Previous Close | 10.58 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 53.70 | Earnings Rating | — | |
| Market Cap | 68.54M | Earnings Date | - | |
| Alpha | 0.02 | Standard Deviation | 0.03 | |
| Beta | -0.41 |
Today's Price Range 10.5810.66 | 52W Range 10.1511.10 |
Summary:
Neutral
| Technical Indicators: | Neutral |
| Moving Averages: | Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.76% | ||
| 1 Month | 0.95% | ||
| 3 Months | 1.16% | ||
| 6 Months | 3.69% | ||
| 1 Year | - | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 709.87 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -0.64 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Leverage Ratio | -332.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 8.40K |
| Shares Outstanding | 0 |
| Shares Float | 6.43M |
| Trades Count | 29 |
| Dollar Volume | 89.16K |
| Avg. Volume | 465 |
| Avg. Weekly Volume | 102 |
| Avg. Monthly Volume | 136 |
| Avg. Quarterly Volume | 1.16K |
Bellevue Life Sciences Unit 1 Com & Wt Exp (NASDAQ: BLACU) stock closed at 10.66 per share at the end of the most recent trading day (a 0.76% change compared to the prior day closing price) with a volume of 8.40K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 0 people. Bellevue Life Sciences Unit 1 Com & Wt Exp CEO is .
The one-year performance of Bellevue Life Sciences Unit 1 Com & Wt Exp stock is %, while year-to-date (YTD) performance is %. BLACU stock has a five-year performance of %. Its 52-week range is between 10.1496 and 11.1, which gives BLACU stock a 52-week price range ratio of 53.70%
Bellevue Life Sciences Unit 1 Com & Wt Exp currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -0.64%, a ROC of -% and a ROE of 709.87%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.
Of the last four earnings reports from Bellevue Life Sciences Unit 1 Com & Wt Exp, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Bellevue Life Sciences Unit 1 Com & Wt Exp’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bellevue Life Sciences Unit 1 Com & Wt Exp is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Bellevue Life Sciences Unit 1 Com & Wt Exp stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bellevue Life Sciences Unit 1 Com & Wt Exp has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Bellevue Life Sciences Unit 1 Com & Wt Exp has a Neutral technical analysis rating based on Technical Indicators (ADX : 35.17, ATR14 : 0.02, CCI20 : 197.81, MACD : 0.02, Money Flow Index : 89.11, ROC : 0.95, RSI : 69.82, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 96.26, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bellevue Life Sciences Unit 1 Com & Wt Exp in the last 12-months were: Kuk Hyoun Hwang (Buy at a value of $4 300 000)
Bellevue Life Sciences Unit 1 Com & Wt Exp
Bellevue Life Sciences Acquisition Corp is a blank check company.
CEO:
Telephone: +1 425 635-7700
Address: 10900 NE 4th Street, Bellevue 98004, WA, US
Number of employees: 0
